Experimental drug: ESK-001 for Safety and Tolerability

"According to the clinicaltrials.gov platform, enrollment for this medical trial is ongoing. The study was initially posted on May 12th 2022 and has since been amended as recently as June 20th 2022."

"As it is a Phase 1 study, with limited evidence of safety and efficacy, our team has judged the risk associated with ESK-001 to be low - scoring it an overall rating of 1."

"Eligibility requirements state that participants must be at least 18 years of age and no older than 60 to join this trial."

"This clinical trial will measure Serious Adverse Events (SAEs) over a fortnight-long period, as its primary outcome. The additional metrics evaluated include the compound's accumulation ratio for AUC(0-τ), apparent plasma elimination half-life (t½λz), and tyk2 pathway inhibition by ESK001 via evaluation of cytokine induction of pSTAT expression and downstream cytokine production - all within the span of 14 days."

"Affirmative. According to data from clinicaltrials.gov, this medical trial is presently seeking participants; the listing was first uploaded on May 12th 2022 and updated for the final time on June 20th 2022. 48 subjects need to be recruited from a single research centre."

"This experimental work is including 48 individuals that are deemed safe and tolerable, ranging between 18 to 60 years old. The list of qualifications for consideration include being a man or woman within the specified age range, possessing good health as verified by medical history reviews, physical exams, vital signs test results and lab parameters. Additionally there may be other factors listed in the protocol that must be met prior to acceptance into the study."